基于两阶段激光诱导视网膜下纤维化小鼠模型的新型AMD眼纤维化特征
本研究通过两阶段激光诱导视网膜下纤维化小鼠模型,在第二次损伤后第3、6、10天对视网膜色素上皮/脉络膜组织进行RNA测序,识别出88个持续上调的核心纤维化基因特征,并在独立小鼠数据集和多个人类AMD RNA测序数据集中交叉验证。该特征富集于上皮-间质转化、补体激活和炎症通路,呈脉络膜特异性表达,并在人类纤维化组织中验证了关键基因与肌成纤维细胞样细胞和小胶质细胞的共定位。
要点
- 两阶段激光模型可诱导持续存在的脉络膜特异性眼纤维化基因特征。
- 88个持续上调基因特征在独立小鼠和人类AMD数据集中交叉验证。
- 关键基因tenascin C、TIMP1和APLNR在人类纤维化组织中验证。
核心结论
- 识别出一种新型、持续存在、脉络膜特异性的眼纤维化特征,具有强跨物种保守性。
研究设计与样本
- 对两阶段激光诱导视网膜下纤维化小鼠模型第二次损伤后第3、6、10天的RPE/脉络膜组织进行RNA测序。
- 在独立小鼠数据集GSE189555和多个人类AMD RNA测序数据集GSE115828、GSE146887、GSE135092中交叉验证。
- 通过免疫荧光在人类视网膜下纤维化组织和年龄匹配组织中验证关键特征基因。
主要发现
- 观察到由88个持续上调基因组成的新核心纤维化特征,在所有时间点均存在。
- 该特征富集于上皮-间质转化、补体激活和炎症通路,呈脉络膜特异性表达,视网膜受累极少。
- 在独立慢性小鼠数据和多个人类AMD数据集(外周视网膜、手术切除的CNV膜和黄斑RPE/脉络膜)中证实该特征在晚期疾病阶段进行性富集。
- 在人类纤维化组织中验证了tenascin C、TIMP1和APLNR关键基因,并显示与肌成纤维细胞样细胞和小胶质细胞共定位。
临床怎么用
- 该纤维化特征可作为转化工具,用于理解视网膜下纤维化发展及开发针对新生血管性AMD的抗纤维化靶向治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Subretinal fibrosis is a major cause of irreversible vision loss in neovascular age-related macular degeneration (AMD), yet no effective antifibrotic therapies exist due to poorly defined molecular drivers. This study aimed to derive and validate a persistent ocular fibrosis signature using the two-stage laser-induced subretinal fibrosis mouse model and to assess its translational relevance in human AMD. METHODS: RNA sequencing (RNA-seq) was performed on retinal pigment epithelium (RPE)/choroid tissues collected at days 3, 6, and 10 following the second laser injury in the two-stage model. A novel core fibrosis signature of 88 persistently upregulated genes was observed across all time points and cross-validated in an independent mouse dataset (GSE189555) and multiple human AMD RNA-seq datasets (GSE115828, GSE146887, GSE135092), including surgically extracted choroidal neovascularization (CNV) membranes and macular RPE/choroid samples. Key signature genes were further validated by immunofluorescence in human subretinal fibrotic and age-matched tissues. RESULTS: The novel ocular fibrosis signature was enriched in epithelial-mesenchymal transition, complement activation, and inflammatory pathways and showed choroid-specific expression with minimal retinal involvement. Cross-validation on independent chronic mouse data and multiple human AMD datasets (peripheral retina, surgically extracted CNV membranes, and macular RPE/choroid) confirmed a progressive enrichment in advanced disease stages. Immunofluorescence in human fibrotic tissue validated key genes (tenascin C, tissue inhibitor of metalloproteinases 1, and apelin receptor) and showed colocalization with myofibroblast-like cells and microglia. CONCLUSIONS: We identified a novel, persistent, choroid-specific ocular fibrosis signature with strong cross-species conservation, highlighting fibrogenic-associated drivers and providing a valuable translational tool to understand subretinal fibrosis development and targeted antifibrotic therapies in neovascular AMD.
引用
- Hughes D, Larue AEM, Taus P, et al. A Novel Ocular Fibrosis Signature for AMD Using the Two-Stage Laser-Induced Subretinal Fibrosis Mouse Model. Invest Ophthalmol Vis Sci. 2026. PMID: 42615798. doi:10.1167/iovs.67.10.49
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。